no more compounding glp 1 drugs FDA restricts GLP-1 ingredients in non-approved compounded | FDA posted on the topic FDA Cracks Down on Compounded
Description
PMID: 29107282
Obesity, diabetes, and liver disease in relation to cardiovascular risk

During the second round of voting, 15 out of 16 questionnaires were returned
"But it's not just about the weight

The obesity epidemic affecting our youth requires innovative approaches, and GLP-1 RAs may represent an important advancement in our therapeutic armamentarium

In the United States, 42.4% of adults meet obesity clinical criteria, while only 2.3% of eligible patients currently receive prescription anti-obesity medication
